Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23612179 | 0.83 | F2 (0.36) | F2PLAUELANEGAAMGAM | |
| SCHEMBL21850242 | 0.82 | TLR8 (0.35) | F2PLAUELANEGAAMGAM | |
| SCHEMBL16985537 | 0.81 | GAA (0.33) | F2PLAUELANEGAAMGAM | |
| SCHEMBL16985551 | 0.80 | F2 (0.33) | F2PLAUELANEGAAMGAM | |
| SCHEMBL18283692 | 0.77 | GSK3B (0.35) | F2PLAUELANEGAAMGAM | |
| SCHEMBL174612 | 0.76 | F2 (0.41) | F2PLAUELANEGAAMGAM | |
| SCHEMBL23612281 | 0.76 | F2 (0.35) | F2PLAUELANEGAAMGAM | |
| SCHEMBL23612219 | 0.76 | MPO (0.36) | F2PLAUELANEGAAMGAM | |
| SCHEMBL17199541 | 0.74 | F2 (0.35) | F2PLAUELANEGAAMGAM | |
| SCHEMBL16985313 | 0.74 | GABRA1 (0.38) | F2PLAUELANEGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273236-B2 | Macrocyclic factor XIa inhibitors bearing heterocyclic groups | BRISTOL-MYERS SQUIBB (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273236-B2 | Macrocyclic factor XIa inhibitors bearing heterocyclic groups | BRISTOL-MYERS SQUIBB (US) | 2019-04-30 | — | — | US | disclosed |
| CN-106459051-B | Macrocyclic FXIA Inhibitors Containing Heterocyclic Groups | 百时美施贵宝公司 | 2018-10-16 | — | — | CN | disclosed |
| US-20180222907-A1 | MACROCYCLIC FACTOR XIA INHIBITORS BEARING HETEROCYCLIC GROUPS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222907-A1 | MACROCYCLIC FACTOR XIA INHIBITORS BEARING HETEROCYCLIC GROUPS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222907-A1 | MACROCYCLIC FACTOR XIA INHIBITORS BEARING HETEROCYCLIC GROUPS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170342071-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL MYERS SQUIBB CO (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342071-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL MYERS SQUIBB CO (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342071-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL MYERS SQUIBB CO (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3099688-B1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3099688-B1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170057961-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057961-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057961-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | US | disclosed |
| CN-106459051-A | Macrocyclic FXIA Inhibitors Containing Heterocyclic Groups | 百时美施贵宝公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3099688-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015116882-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015116882-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057961-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | TFPI, TFPI2, F2 | F2 3/4885PLAU 38/4885ELANE 182/4885 |
| US-20170342071-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | TFPI, TFPI2, F2 | F2 3/4885PLAU 38/4885ELANE 182/4885 |
| US-20180222907-A1 | MACROCYCLIC FACTOR XIA INHIBITORS BEARING HETEROCYCLIC GROUPS | TFPI, TFPI2, F11 | F2 5/4885PLAU 29/4885ELANE 152/4885 |
| US-10273236-B2 | Macrocyclic factor XIa inhibitors bearing heterocyclic groups | TFPI, TFPI2, F11 | F2 5/4885PLAU 29/4885ELANE 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.